RxDoctor Payments Data

Anthony Patrello, MD

Interventional Cardiology · Poughkeepsie, NYNPI 1861652547

Payments from drug & device makers

$30,498in general payments, 2019–2025

Across 145 payments — averaging $210.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$17K
  • Pfizer$11K
  • Boston Scientific$785
  • Abiomed$551
  • AstraZeneca$326
  • Novartis$305
  • plus $917 from 10 others

What the payments were for

  • Speaking & faculty fees$14,28579%
  • Travel & lodging$1941%
  • Food & beverage$3,56420%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,498 in reported general payments places this provider in the 65th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$426,633
Medicare patients
1,345
Services billed
4,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$233,076
EntrestoSacubitril/Valsartan70$119,783
XareltoRivaroxaban44$47,793
FarxigaDapagliflozin Propanediol24$33,281
Praluent PenAlirocumab41$31,320
BrilintaTicagrelor20$21,470
Dofetilide13$8,409
Rosuvastatin Calcium319$6,765
Atorvastatin Calcium447$4,953
Metoprolol Succinate315$4,466
Ezetimibe114$4,041
Amlodipine Besylate289$2,135
Diltiazem 24hr Er (Cd)Diltiazem Hcl66$2,075
Valsartan67$2,030
Labetalol Hcl36$2,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11,047$233,076179 claims
NovartisEntresto$305$119,78370 claims
AstraZenecaFarxiga, Brilinta$326$54,75044 claims
Johnson & JohnsonXarelto$251$47,79344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →